Trial Profile
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Erlotinib; Paclitaxel; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower130
- Sponsors Roche
- 12 Sep 2023 Results of pooled analysis fromIMpower150, IMpower131, IMpower130; analyzing prognostic value of Lung Immune Prognostic Index (LIPI) in 1st-line CT +/- IT +/- antiangiogenics (AA), and its potential role in guiding treatment selection. presented at the 24th World Conference on Lung Cancer
- 06 Apr 2023 Results of pololed analysis from BIRCH, FIR, IMpower130, IMpower131, IMpower150, OAK, and POPLAR trials published in the Oncologist
- 13 Sep 2022 Results from NCT02367781; NCT02366143; NCT02008227 assessing whether Radiotherapy enhances the activity of ICI, presented at the 47th European Society for Medical Oncology Congress